FdaApplication
NDA 018102
Identifiers
- fda_app_no: NDA018102
Properties
| Property | Value |
|---|---|
| applicant_name | PHARMACIA AND UPJOHN CO |
| application_type | NDA |
Revenue by product
MEDROL
| Period | Revenue |
|---|---|
| Q4 2023 | $76.0M |
| Q3 2023 | $89.0M |
| Q2 2023 | $80.0M |
| Q1 2023 | $93.0M |
| Q4 2022 | $93.0M |
| Q3 2022 | $79.0M |
| Q2 2022 | $79.0M |
| Q1 2022 | $76.0M |
| Q4 2021 | $112.0M |
| Q3 2021 | $109.0M |
| Q2 2021 | $112.0M |
| Q1 2021 | $99.0M |
| Q4 2020 | $107.0M |
| Q3 2020 | $87.0M |
| Q2 2020 | $78.0M |
| Q1 2020 | $129.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| MEDROL | METHYLPREDNISOLONE ACETATE | 40MG/BOT | ENEMA;RECTAL |
1 product